Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Mucositis Stories

2013-08-21 23:27:11

Hamacher awards one and two star rating to five MedActive® Oral Relief Brands. Spring Hill, FL (PRWEB) August 21, 2013 MedActive is pleased to announce that five (5) MedActive® Oral Relief Brands have been awarded one- and two-star ratings by Hamacher Resource Group, a leader in market research and category management for the retail pharmacy segment. Wholesaler load-in and pharmacy planogram placement is scheduled to begin September 1, 2013. Hamacher provides new product...

2013-08-12 08:28:28

Current Cash Resources Total $8.1 Million PRINCETON, N.J., Aug. 12, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today its financial results for the quarter and six months ended June 30, 2013. Soligenix's revenues for the quarter and six months ended were $0.6 million as...

2013-07-12 04:21:20

MILAN,Italy and SHANGHAI, July 12, 2013 /PRNewswire/ -- BMG Pharma S.r.l and Luqa Pharmaceuticals are pleased to announce a long-term partnership for the commercialization of BMG's products in China and Hong Kong. Under the terms of this agreement, Luqa will exclusively register and commercialize BMG's highly innovative dermatology, oral care and Cancer Support Therapy products. The agreement will enable Luqa to rapidly expand its dermatology offering and enter the...

2013-07-08 08:26:34

Access to SciClone Oral Mucositis Clinical Data Enables Personalized Medicine Approach for Design of Clinical Trials PRINCETON, N.J., July 8, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone...

2013-06-27 08:29:39

Met Primary Endpoint of Statistically Significant Reduction in Mouth and Throat Soreness Associated With Oral Mucositis; MuGard Patients Also Had Decreased Severity of Oral Mucositis by WHO Score DALLAS and NEW YORK, June 27, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented top-line results today from a phase IV clinical trial evaluating...

2013-06-26 08:30:40

PRINCETON, N.J., June 26, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that on June 25, 2013 it closed its previously announced registered public offering. The Company raised gross proceeds of approximately $7.1 million in the offering and intends to...

2013-06-21 08:24:43

PRINCETON, N.J., June 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today the pricing of a registered public offering of shares of common stock and warrants to purchase common stock. In connection with the public offering, the Company has entered into...

2013-06-10 23:20:20

IndUS will develop and commercialize APS intellectual property to treat oral mucositis, a significant unmet medical need for cancer patients. Mountain View, CA (PRWEB) June 10, 2013 Applied Protein Sciences (APS), a privately held biotech company founded in 2007 in Mountain View, CA, announces that it has been acquired by IndUS Pharmaceuticals (IndUS), a privately held Boston based pharmaceutical company. The acquisition gives IndUS the ability to extend its pipeline to include preclinical...

2013-06-10 08:30:23

DALLAS and NEW YORK, June 10, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) related to the commercialization of MuGard(TM) in the US and its territories. Under the terms of the license agreement, Access will receive an upfront licensing fee of $3.3 million and a tiered, double digit royalty on net sales of MuGard in...

2013-06-03 08:27:40

PRINCETON, N.J., June 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration (FDA). Fast track is a designation that the FDA reserves for a drug intended to treat a...